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The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study 
is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for 
postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET.  In this initial 
report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in 
Japan.  Baseline data for the 50 patients enrolled in HORSE-BC were analyzed,  including patient characteris-
tics,  types of secondary ET,  and reasons for selecting secondary ET.  Postoperative recurrence was detected in 
84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50).  Forty-one patients (41/50; 82%) 
received fulvestrant,  5 patients (10%) received selective estrogen receptor modulators (SERMs),  3 patients (6%) 
received ET plus a mammalian target of rapamycin (mTOR) inhibitor,  and 1 patient received an aromatase 
inhibitor (AI) as the secondary ET.  Forty-five patients selected their secondary ET based on its therapeutic 
effect,  while 14 patients selected it based on side effects.  Most patients with progression after primary ET 
selected fulvestrant as the secondary ET based on its therapeutic and side effects.  We await the final results from 
the HORSE-BC study.
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M etastatic breast cancer (MBC) typically requires life-long treatment,  which aims to prolong sur-
vival and improve/protect quality of life.  Thus,  treat-
ment for MBC is selected based on the cancer’s clinical 
and pathological characteristics,  especially regarding 
the statuses for estrogen receptor (ER),  progesterone 
receptor (PR),  and human epidermal growth factor 
receptor type 2 (HER2),  which predict clinical response 
and prognosis.  An algorithm was proposed by 
Hortobagyi [1] to help guide this treatment selection 
process.  Endocrine therapies (ETs) are the mainstay of 
treatment for hormone receptor-positive (HR+) can-
cers,  and aromatase inhibitors (AI) have become the 
preferred first-line treatment among postmenopausal 
patients [2 , 3].  Unfortunately,  some patients do not 
respond to first-line ET because of primary or acquired 
resistance [4].  Thus,  after disease progression,  the sec-
ond-line treatment options include other steroid or 
nonsteroidal classes of AIs,  fulvestrant (an ER antago-
nist),  tamoxifen,  and molecularly-targeted therapies 
(e.g.,  inhibitors of mammalian target of rapamycin 
[mTOR] and cyclin-dependent kinase [CDK4/6]) [5-8].  
In cases that respond to primary ET,  continued ET is 
needed because even secondary ET has an antitumor 
effect after the primary ET loses its efficacy.  However,  it 
remains challenging to treat cases with resistance to the 
primary ET,  which indicates low sensitivity to ET.
Several models for classifying ET sensitivity and tol-
erance have been proposed based on the clinical course 
of the initial ET.  For example,  the second International 
Consensus Guidelines for Advanced Breast Cancer pro-
posed classifying ET resistance for ER+ MBC based on 
the time from ET initiation to progression [9],  with 
primary resistance defined as relapse during the first 2 
years of adjuvant ET or disease progression during the 
first 6 months of first-line ET.  Secondary (acquired) 
endocrine resistance was defined as relapse at > 2 years 
during adjuvant ET,  or relapse within 12 months of 
completing adjuvant ET,  or for MBC,  progression at ≥ 6 
months after initiating ET while on ET.  In addition,  
“very low” drug sensitivity has been proposed as a clas-
sification for cases with recurrence during the first 2 
years after starting postoperative adjuvant ET or during 
the first 3 months after starting first-line ET,  with “low” 
drug sensitivity defined as cases with recurrence at > 2 
years after starting postoperative adjuvant ET [4].  Thus,  
a clinically significant treatment effect may be obtained 
using secondary ET,  even in cases with low sensitivity 
to the primary ET.  However,  endocrine resistance is a 
significant problem in treating breast cancer,  as 
approximately 30% of patients with MBC regress 
during initial ET and an additional 20% have prolonged 
stable disease [4 , 10].  The durations of response to sec-
ond and subsequent lines of therapy are substantially 
lower [11 , 12].  Nevertheless,  no clinical trials have 
evaluated the efficacy and safety of the numerous avail-
able secondary ETs for cases with poor responsiveness 
to the primary ET.
The Hormonal therapy resistant estrogen-receptor 
positive metastatic breast cancer cohort (HORSE-BC) 
study is a multicenter observational study that is cur-
rently underway to evaluate the efficacy and safety of 
secondary ETs among postmenopausal ER+ HER2– 
cases of MBC that did not respond favorably to primary 
ET,  and to clarify the effect of any reactivity to the pri-
mary ET based on the tumor characteristics.  This infor-
mation will be useful to complement Hortobagyi’s ther-
apeutic algorithm.  In this initial report,  we analyze the 
baseline data from HORSE-BC to provide a description 
of the current status of treatment selection for MBC in 
Japan.
Patients and Methods
The multicenter observational HORSE-BC study is 
currently evaluating therapies that were selected based 
on physician and patient preferences in 50 cases that 
were registered between February 2016 and January 
2017 [13].  This study’s protocol was approved by our 
institutional review board (protocol number :  
K1606-001) and all patients provided written informed 
consent.  The major inclusion criteria were 1) post-
menopausal status; 2) stage IV breast cancer at the first 
visit or breast cancer with progression or recurrence 
after treatment; 3) planned ET for MBC; 4) previous 
ET using any endocrine drug as (a) continuous postop-
erative adjuvant therapy with recurrence within 5 years 
after starting ET or (b) initial treatment for MBC with 
disease progression within 9 months after starting ET;  
and 5) no previous chemotherapy for breast cancer or 
adjuvant chemotherapy during the last 6 months.  Cases 
where ≥ 1% of the tumor cells stained positive for ER 
and/or for PR were considered HR+,  while HER2– 
cases were defined as having an immunohistochemistry 
score of 0/1+ or a HER2/CEP 17 ratio < 2.0 using fluo-
rescence in situ hybridization.
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The treatment choices were various medicines that 
are covered by the Japanese Medical Insurance as ET for 
postmenopausal breast cancer,  excluding ET drugs that 
were used in the patient’s previous treatment.  Treat-
ments were selected based on a discussion between the 
physician and patient,  and their safety and efficacy were 
monitored for each of 3 patient groups: an SERM 
group (patients who received tamoxifen or toremifene,  
which are selective estrogen receptor modulators 
[SERMs]),  an AI group (patients who received anastro-
zole,  letrozole,  or exemestane),  a SERD group (patients 
who received fulvestrant,  which is a selective estrogen 
receptor down-regulator [SERD]),  and an mTORi 
group (patients who received any combination of ET 
and everolimus,  which is an mTOR inhibitor).
In this initial report,  we analyze the baseline data of 
the HORSE-BC,  including the patient characteristics,  
types of adjuvant and first-line ET,  types of secondary 
ET,  and reasons for selecting the secondary ET,  in 
order to provide a description of the current status of 
treatment selection for MBC in Japan.
Results
The characteristics of the 50 patients are summa-
rized in Table 1.  The median age was 66 years (range:  
41-88 years),  and the median body mass index (BMI) 
was 23.4 kg/m2 (range: 16.4-31.9 kg/m2).  All patients 
were ER+ and 80% (40/50) were PR+.  Most patients 
(49/50) had a pre-treatment PS value of 0-1,  with 90% 
(45/50) having invasive ductal carcinoma and 10% (5/50) 
having invasive lobular carcinoma.  Postoperative recur-
rence was detected for 84% of the patients (42/50),  and 
this recurrence group had a median duration of 30.5 
months between surgery and recurrence (range: 5.3-
58.9 months).  De novo stage IV breast cancer was 
detected in 16% of the patients (8/50),  and these 
patients had a median first-line ET duration of 5 
months (range: 2.3-10.8 months).  No adjuvant chemo-
therapy was provided to 42% of the patients (21/50),  
and 58% (29/50) received adjuvant chemotherapies 
including anthracycline- and/or taxane-containing reg-
imens.  
The adjuvant and first-line ETs are summarized in 
Table 2.  Twenty patients with recurrence after surgery 
(20/42; 47.6%) received letrozole as the adjuvant ET,  
17 patients (40.4%) received anastrozole,  2 patients 
received exemestane,  and 3 patients received tamoxifen.  
Five cases of de novo stage IV cancer (5/8; 62.5%) were 
treated using letrozole,  and the remaining cases were 
treated using anastrozole (2 cases) or tamoxifen (1 case).
The secondary ETs are summarized in Table 3.  
Forty-one patients (41/50; 82%) received fulvestrant,  5 
patients (10%) received SERMs,  3 patients (6%) received 
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Table 1　 Patient characteristics
Age (years) 66 (41-88)
BMI (kg/m2) 23.4 (16.4-31.9)
ER
　0% 0 0%
　1-9% 0 0%
　≥10% 50 100%
PR
　0% 10 20%
　1-9% 8 16%
　≥10% 32 64%
PS
　0 42 84%
　1 7 14%
　2 1 2%
　3 0 0%
　4 0 0%
Histological type
　IDC 45 90%
　ILC 5 10%
TNM staging at initial diagnosis
　I 2 4%
　II 21 42%
　III 18 36%
　IV 8 16%
　Unknown 1 2%
Data are reported as the median (range) or a number and percent-
age.
BMI,  body mass index; ER,  estrogen receptor; PR,  progesterone 
receptor; PS,  performance status; IDC,  invasive ductal carcinoma;  
ILC,  invasive lobular carcinoma.
Table 2　 Adjuvant and ﬁrst-line endocrine therapy
Adjuvant endocrine therapy Patients
　Letrozole 20 47.6%
　Anastrozole 17 40.5%
　Exemestane 2 4.8%
　Tamoxifen 3 7.1%
First-line endocrine therapy
　Letrozole 5 62.5%
　Anastrozole 2 25.0%
　Exemestane 0 0%
　Tamoxifen 1 12.5%
ET plus an mTOR inhibitor,  and only 1 patient received 
an AI.  In collaboration with their physicians,  45 
patients selected their secondary ET based on its 
expected therapeutic effect,  14 patients selected it based 
on side effects,  and 2 patients selected it based on cost 
(multiple answers were allowed) (Table 3).
Discussion
The present study revealed that most patients with 
progression after primary ET had low sensitivity and 
selected fulvestrant as a secondary ET.  In this context,  
fulvestrant suppresses estrogen signaling by binding to 
ER and inducing a conformational change [14 , 15],  
which subsequently blocks dimerization and triggers 
accelerated degradation and down-regulation of ER 
[14].  Fulvestrant may exhibit a lack of cross-reactivity 
with tamoxifen,  and cancers that progress during ful-
vestrant treatment may remain sensitive to further ET 
[16].  Ellis et al.  have reported that fulvestrant treatment 
(500 mg) improved overall survival,  compared to anas-
trozole,  in the first-line setting for ER+ advanced breast 
cancer [17].  First-line fulvestrant therapy (500 mg) is 
also supported by the results of the phase III dou-
ble-blind FALCON trial [18],  which evaluated patients 
with locally advanced or metastatic breast cancer using 
a strict definition for ET-naïve disease [18].  In addition,  
the comparison of 500 mg versus 250 mg of fulvestrant 
in the CONFIRM trial revealed that the higher dose 
provided an overall survival advantage in the sec-
ond-line setting [19].  Moreover,  treatment was associ-
ated with only mild or moderately severe adverse events 
(e.g.,  arthralgia),  which did not require treatment 
interruption or lead to mortality [18 , 19].  However,  
during the enrolment period for the present study,  ful-
vestrant was not approved as a first-line ET for advanced 
or stage IV breast cancers in Japan,  although it has sub-
sequently been approved for HR+ advanced or stage IV 
breast cancers,  which will significantly change the 
selection of first-line ET in Japan.
Interestingly,  only 3 patients selected mTOR inhibi-
tor treatment.  The combination of an mTOR inhibitor 
plus a steroidal AI is a valid option for some postmeno-
pausal patients who experience progression after non- 
steroidal AI treatment,  as it significantly prolongs pro-
gression-free survival (PFS),  although it does not 
improve overall survival [20].  Nevertheless,  a higher 
proportion of patients discontinue mTOR inhibitor 
treatment because of adverse events (29%) [20],  which 
is consistent with earlier reports [7 , 21].  Thus,  combi-
nation treatments should be considered on a case-by-
case basis,  especially in the context of related toxicities 
[22].  The present study revealed that side effects were 
the second most important factor influencing treatment 
selection.  In this context,  the combination of ET and 
CDK4/6 inhibitors is the most important advance for 
managing HR+ cases,  and first-line AI plus CDK4/6 
inhibitor therapy for postmenopausal patients provides 
a significant improvement in PFS,  with an acceptable 
toxicity profile,  although the overall survival benefit 
remains unclear [22].
Cost was the third most important factor influenc-
ing treatment selection in the present study.  In this 
context,  drugs receiving accelerated approval enter the 
market as Food and Drug Administration-approved 
products,  despite unclear evidence regarding their clin-
ical benefit,  and insurers must decide whether and how 
to pay for them.  Those decisions are becoming increas-
ingly complex in light of the rising prices for drugs [23].  
Thus,  it is important to identify patients with the great-
est anticipated benefit,  although there are no biomark-
ers (aside from HR status) for predicting the benefit 
from drugs.  It is possible that ESR1 mutation will be a 
biomarker for HR+ advanced breast cancers after pro-
longed AI treatment,  as the SoFEA study revealed 
improved PFS in patients with this mutation who 
received fulvestrant (vs. exemestane),  whereas no sig-
nificant difference was observed among patients with 
the wildtype ESR1 [24].  Moreover,  the PALOMA3 
study revealed ESR1 mutations in plasma samples from 
25.3% of patients with other mutations that were associ-
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Table 3　 Preference of secondary endocrine therapy in this 
cohort＊
Agents SERMs AIs SERD mTORi
Number of cases 5 1 41 3
Reasons for choice
　Therapeutic eﬀects 5 1 36 3
　Side eﬀects 1 0 13 0
　Cost 0 0 2 0
　Others 0 0 2 0
SERMs,  selective estrogen receptor modulators; AIs,  aromatase 
inhibitors; SERD,  selective estrogen receptor down-regulator;  
mTORi,  the combined use of an endocrine therapy and everolimus.  
Multiple answers were allowed.
ated with acquired resistance to prior AI.
The main strength of the present study was that the 
patients and physicians were able to select any endo-
crine agent without a defined treatment algorithm.  This 
information is important,  as better data are needed to 
clarify the efficacy and safety of secondary ETs for 
breast cancer with low sensitivity to the primary ET,  
and to facilitate evidence-based selection of an appro-
priate secondary ET.  In conclusion,  the baseline data of 
the HORSE-BC study revealed that most patients with 
progression after primary ET selected fulvestrant as the 
secondary ET based on its therapeutic and side effects.  
We await the final results from this study.
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